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Abstract
Background Early biomarkers of skeletal muscle anabolism
will facilitate the development of therapies for sarcopenia
and frailty.
Methods and results We examined plasma type III collagen
N-terminal propeptide (P3NP), skeletal muscle protein
fractional synthesis rate, and gene and protein expression
profiles to identify testosterone-induced changes in muscle
anabolism. Two placebo-controlled studies enrolled
community-dwelling men (study 1, 60–75 years; study 2,
18–40 years) with low to normal testosterone levels. Men
were randomized to lower dose (study 1, 100 mg; study 2,
200 mg) or higher dose (study 1, 300 mg; study 2, 600 mg)
single intramuscular testosterone or saline injection. After
1 week, testosterone acutely increased plasma P3NP levels
in a dose-dependent manner and altered the expression of
several skeletal muscle transcripts and proteins. Though
not statistically significant, mixed muscle protein
fractional synthesis rate tended to increase (1.08-fold
with 100 mg testosterone, 1.12-fold with 300 mg
testosterone). Testosterone exposure also increased
skeletal muscle expression of the collagen type III gene
that encodes P3NP.
Conclusion P3NP is a potentially useful early biomarker
for muscle anabolic therapy. Skeletal muscle protein and
RNA profiling are useful tools for the discovery of novel
muscle anabolic biomarkers.
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ANCOVA Analysis of covariance
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Muscle size and strength deteriorate dramatically with increas-
ing age. Sarcopenia can be defined operationally as muscle
mass two standard deviations below that of young healthy
controls. The prevalence of sarcopenia in individuals older
than 80 years of age exceeds 50%. Exercise training can
improve sarcopenia, but there are currently no marketed
treatments available for sarcopenia [1–3]. Loss of muscle
mass and function threatens the independence and quality of
life of the elderly and may compromise their ability to survive
critical illness [4]. Further understanding of the pathophysi-
ology of sarcopenia and the development of more sensitive
and specific genotyping and phenotyping tools will enable us
to develop targeted therapeutic agents to treat this disorder.
A challenge in developing drug therapies for sarcopenia is
the long treatment duration required for assessing clinical
efficacy. Currently, we assess clinical efficacy by quantifying
changes in lean body mass using dual-energy X-ray absorpti-
ometry and changes in muscle function by using bilateral leg
maximum voluntary force production, but measurable
improvement in these endpoints requires at least 12 weeks
of follow-up. We hypothesized that short-term testosterone
exposure would induce several candidate early predictive
biomarkers of muscle anabolism that could be identified using
skeletal muscle gene and protein expression profiling plat-
forms. Testosterone enanthate was used because it is a potent
a n a b o l i ca g e n tk n o w nt oi m p r o v em u s c l es i z ea n ds t r e n g t h
[5, 6]. Sarcopenia can affect women, but to minimize
heterogeneity, only men were enrolled given there are clear
data regarding the effects of testosterone in men [5–7].
Severalexistingcandidatebiomarkersformuscleanabolism
were examined. Collagen type III is the characteristic collagen
of parenchymal organs and soft connective tissues such as
muscle and skin. Collagen III is synthesized from larger
procollagen type III with cleavage of peptide fragments from
the N- and C-terminal ends. Procollagen type III N-terminal
peptide (P3NP) is released into the circulation during collagen
III synthesis and increases when skeletal muscle remodeling is
activated [8]. Skeletal muscle protein fractional synthesis rate
(FSR) increases with muscle protein anabolism and can be
assessed by measuring the rate of incorporation of stable
isotope-labeled phenylalanine into skeletal muscle proteins.
Muscle RNA microarray and protein expression profiling are
newerhigh-throughputapproachesthatcanbeusedtoexamine
transcript andproteinexpressionchangesandcanbeusefulfor
discovering new candidate biomarkers for myoanabolism.
2 Materials and methods
The study protocols were approved by the institutional
review boards at the participating study centers. All
participants provided verbal and written informed consent
before undergoing any study procedures. Patients were
recruited at Celerion (formerly MDS Pharma Services), 22-
24 Lisburn Road, Belfast, Northern Ireland, BY9 6AD. The
same ethics committee approved both studies, the Plymouth
Independent Ethics Committee, ITTC Building 2, Room
107, Tamar Science Park, Derriford, Plymouth, Devon, PL6
8BX.
2.1 Study design
Both trials were randomized, placebo-controlled, single-
blind single-dose studies. Participants were blinded to
treatment; the investigators and sponsor were not blinded
for safety reasons. The primary objective of study 1 was to
evaluate the utility of the in vivo quantitation of skeletal
muscle protein FSR as an early biomarker for testosterone-
induced muscle protein anabolism. Twenty-two healthy 60- to
7 5 - y e a r - o l dm e nw e r er a n d o m i z e dt oo n eo ft h r e eg r o u p s :
low-dose (100 mg, n= 6 )o rh i g h - d o s e( 3 0 0m g ,n=8)
intramuscular (IM) testosterone enanthate or IM saline
injection (n=8). Intramuscular injection was performed on
the gluteus maximus muscle. FSR was measured before
(baseline) and 7 days (1 week) after testosterone/saline
injection. The primary objective of study 2 was to evaluate
testosterone-induced alterations in muscle protein expres-
sion profiles using mass spectrometry-based high-
throughput comparative proteomics profiling. Twenty-eight
healthy 18- to 40-year-old men were randomized to one
of three groups: low-dose (200 mg, n=9), high-dose
(600 mg, n=10) IM testosterone enanthate or IM saline
injection (n=9).Vastus lateralis muscle and blood samples
were obtained after an overnight fast at baseline (before
the testosterone/saline injection, day 0) and 7 days after
the single testosterone/saline injection (day 7). Muscle and
blood samples were processed as above.
Serum P3NP concentration and skeletal muscle mRNA
microarray profiling were examined in both studies.
2.2 Participants
Healthy community-dwelling men between the ages of 60
and 75 years (study 1) with low–normal testosterone levels
(9.7–17.3 nmol/L) or 18 and 40 years (study 2) with low–
normal testosterone levels (9.7–24.6 nmol/L) and prostate-
specific antigen≤4.0 ng/mL were enrolled. Because older
men may experience more side effects from higher doses of
testosterone [6], the 600-mg testosterone dose was only
administered to younger men (18–40 years old) in study 2.
Participants were nonsmokers, with body mass index of
21–30kg/m[2] and stable weight for 3 months by self-report.
Participants agreed to follow the meat-free controlled protein
diet and avoid strenuous physical activity during the study.
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steroids, growth hormone (GH), GH secretagogues, or
other anabolic agents in the previous 12 months; oral,
inhaled, or nasal glucocorticoids; inflammatory modulators
such as ibuprofen, etoricoxib, or celecoxib; and blood anti-
coagulants or high doses of aspirin.
2.3 Testosterone concentration
Serum total testosterone was quantified using immuno-
assay (Roche Diagnostics, Indianapolis, IN, USA). Free
testosterone was quantified using the Coat-A-Count Free
Testosterone radioimmunoassay kit (Siemens Medical
Solutions Diagnostics, Deerfield, IL, USA).
2.4 Procollagen III N-terminal peptide
Serum P3NP concentration was quantified using a
commercial equilibrium radioimmunoassay (reference
range 2.3–6.4 ng/mL, sensitivity 0.8 ng/mL; UniQ
PIIINP RIA kit, Orion Diagnostica, Finland) [9].
2.5 Assessment of muscle protein fractional synthetic rate
A primed (3 μmol/kg) 12-h constant intravenous infusion
(3 μmol kg
−1 h
−1)o f
13C6-phenylalanine (
13C6-phe;
dissolved in sterile saline; ~95%
13C6, Cambridge Isotope
Laboratories Inc., Andover, MA, USA) was used to
quantify the in vivo rate of phenylalanine incorporation
into mixed skeletal muscle proteins [10, 11]. Using a
Bergström needle biopsy procedure, vastus lateralis muscle
samples (~100 mg) were obtained 2.5–3 and 11.5–12 h
(from the contralateral thigh) after the
13C6-phe infusion
started. Muscle samples were immediately cleaned of
adipose and connective tissues, partitioned, and frozen
(−80°C) for later analysis. Blood samples were obtained
before starting, at 2–3h ,a n da t1 1 –12 h during the
13C6-phe
infusion. Serum or plasma was separated from cells,
partitioned, and frozen for later analysis. After completing
the baseline
13C6-phe infusion, participants received a single
testosterone enanthate or saline injection (IM 100 or 300 mg
testosterone or IM placebo). The procedure for quantifying in
vivo FSR was repeated 7 days after the single testosterone/
saline injection.
Plasma and muscle tissue free pool amino acids were
converted to their N-heptafluorobutyryl n-propyl ester
chemical derivatives [12] and
13C6-phe (m/z 383 and 389)
enrichment (tracer/tracee ratio, TTR) [13] was quantified
using capillary gas chromatography–negative chemical
ionization–mass spectrometry (GC-NCI-MS; Agilent
6890N gas chromatograph and Agilent 5973N mass
selective detector, Palo Alto, CA, USA) [14, 15]. The
GC-NCI-MS instrument response was calibrated using
gravimetric standards of known
13C6-phe enrichment.
Mixed muscle protein
13C6-phe enrichment (TTR) was
quantified using gas chromatography–combustion–isotope
ratio mass spectrometry (Finnigan Delta+XL-IRMS, Bremen,
Germany) [16, 17].
2.6 Comparative proteomics
Muscle proteins were extracted from frozen muscle samples
(20–32 mg) using lysis buffer with protease inhibitor
cocktail (EMD Bioscience, San Diego, CA, USA). Fourier
transform mass spectrometry data were analyzed using
Rosetta Biosoftware Elucidator® System 3.1 (Seattle, WA,
USA) [18]. Further details on proteomics methods are
available in a prior publication [19].
2.7 RNA microarray expression analysis
B e c a u s es t u d y1w a sp r i m a r i l yd e s i g n e dt oa s s e s sF S R ,
muscle samples from two time points (after 3 and 12 h
of
13C6-phe infusion) were available from the baseline and
day 7 infusion studies. These samples provided enough
material for two gene expression analyses that were used
to compare transcript levels between baseline and 7 days
after testosterone/saline injection. During study 2, one
muscle sample was obtained at baseline and at day 7 and
was used to compare the gene expression profiles between
baseline and 7 days after testosterone/saline injection.
Tissue was stored in RNAlater (Ambion, Inc., Austin, TX,
USA) and RNA purified using TRIzol. Sample purification,
amplification, labeling, and microarray processing were
performed by Rosetta Inpharmatics. Cell files were loaded
into Rosetta Biosoftware Resolver® System 7.2. Expression
summaries were calculated using Robust Multichip Analysis
via Affymetrix Power Tool with only perfect match (PM)
probesincluded.MAS5.0p values were calculated with both
PM and MM (mismatch) probes included.
2.8 Statistical methods
The assessments of P3NP, total/free testosterone, and FSR
were performed after log transformation using an unequal
variance ANCOVA model with a treatment term and
baseline as covariate. No deviations from normality were
observed. Heterogeneity of variance reduced after log
transformation. The primary comparisons were based on
the mean (fold) changes from baseline between two
testosterone doses and placebo. A difference (expected to
be >0) was considered significant if its one-sided p value
was <0.05. To adjust for multiple comparisons within an
endpoint, a closed stepwise testing procedure was used,
starting with (a) high-dose testosterone vs. placebo and, if
significant, then (b) low-dose testosterone vs. placebo.
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serum total and free testosterone was performed. To further
assess whether serum testosterone levels predicted P3NP,
regression models including the terms study, dose, and with
or without testosterone were fitted to the combined data
from both studies. “Dose” is in the logarithmic scale of the
active doses and set to 0 for placebo. The proportion of
treatment effect on change in P3NP explained by serum
testosterone was derived from the regression models.
Proteomic data were analyzed using a linear mixed
model. Briefly, for each of the 65,152 features with liquid
chromatography retention times between 10 and 45 min,
the 0 intensities were replaced with half the smallest
positive intensity measured for that feature. A linear mixed
model was fitted for each feature using a log intensity scale,
with the six treatment period combinations as fixed effects
and subjects as random effects.
For gene and protein expression, two-sided p values and
95% CIs were derived. The false discovery rate (FDR)
defined as the proportion of significant changes that are
false positives was used to assess significance. Candidate
biomarkers significant on their own (univariate analysis)
between the placebo and testosterone groups were identi-
fied with 10% FDR. Significant group changes in gene
expression from baseline were identified using standard
ANOVA on each study set at two-sided p<0.05. Gene
expression changes from baseline that followed a signifi-
cant trend were identified using the Jonckheere–Terpstra
ordered trend test [20, 21]. The intersection of the ANOVA
gene set and the Jonckheere–Terpstra trending gene set
were used to select gene probe sets for assessing association
with testosterone treatment in muscle.
For P3NP, total/free testosterone and FSR data were
analyzed using SAS 9.1 (SAS Institute Inc., Cary, NC,
USA). The RNA statistical analysis software used was
MatLab (The Mathworks, Natick, MA, USA). The
proteomic statistical analysis software used was R-2.7.0.
(R: A Language and Environment for Statistical Com-
puting, R Foundation for Statistical Computing, Vienna,
Austria; 2010).
3 Results
3.1 Participant demographics and baseline characteristics
In study 1, 22 participants (eight in the placebo arm, six in
the 100 mg, and eight in the 300 mg testosterone arms)
were randomly assigned and completed treatment. One
placebo participant had a muscle biopsy that was inade-
quate for FSR measurement. In study 2, 28 participants
(nine in placebo, nine in 300 mg, and ten in 600 mg
testosterone groups) were randomly assigned; 27 completed
the study and one participant withdrew from the study
following a reaction (10-cm area of induration) at the
testosterone injection site. Baseline testosterone levels were
similar between the study groups (Table 1). For study 1,
baseline mean (±SD) total testosterone was 14.6±2.7 nmol/L
(range 10.5–19.5 nmol/L). For study 2, baseline mean total
testosterone was 18.6±4.5 nmol/L (range 8.7–29.7 nmol/L).
Baseline P3NP levels were similar between groups. In
study 1, baseline mean P3NP level was 3.2±0.7 ng/L
(range 1.8–4 . 6n g / L )a n di ns t u d y2w a s3 . 7 ± 0 . 7n g / L
(range 2.4–5.6 ng/L).
Placebo Low-dose testosterone
a High-dose testosterone
b
Study 1
No. of subjects 8 6 8
Age (years) 67.5 (4.1) 62.3 (2.3) 64.6 (3.9)
Weight (kg) 79.8 (8.5) 76.3 (7.0) 85.8 (7.7)
Body mass index (kg/m
2) 26.7 (2.2) 27.0 (1.9) 27.1 (1.0)
Free testosterone (pg/mL) 8.79 (2.01) 8.92 (1.53) 10.16 (1.74)
Total testosterone (nmol/L) 13.64 (2.87) 14.53 (2.52) 15.51 (2.73)
Plasma P3NP (ng/L) 3.33 (0.95) 3.08 (0.55) 3.13 (0.64)
Study 2
No. of subjects 9 9 10
Age (years) 30.0 (6.1) 26.2 (6.3) 30.1 (5.1)
Weight (kg) 81.7 (9.2) 83.7 (11.2) 81.6 (11.9)
Body mass index (kg/m
2) 25.0 (2.2) 26.7 (2.6) 24.9 (2.3)
Free testosterone (pg/mL) 17.14 (2.84) 16.09 (3.78) 17.80 (3.74)
Total testosterone (nmol/L) 19.79 (3.00) 16.26 (4.49) 19.50 (5.10)
Plasma P3NP (ng/L) 3.51 (0.76) 3.69 (0.80) 3.82 (0.66)
Table 1 Baseline characteristics
for treatment groups
Mean (standard deviation)
aFor study 1, low = testosterone
100 mg. For study 2, low =
testosterone 200 mg.
bFor study 1, high = testosterone
300 mg. For study 2, high =
testosterone 600 mg.
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In both studies, total (Fig. 1a, c) and free testosterone levels
(Fig. 1b, d) increased 7 days after IM testosterone injection
in a dose-dependent manner in comparison to saline
injection. As expected, for each dose administered, there
was considerable inter-participant variability in the total
and free testosterone levels. In study 1, total testosterone
levels increased 1.43-fold from baseline in the 100 mg
IM, 2.53-fold in the 300 mg IM, and 0.9-fold in the
saline IM group (Fig. 1a). In study 2, total testosterone
levels increased 1.84-fold in the 200 mg IM, 2.18-fold in
the 600 mg IM, and 0.95-fold in the saline IM group
(Fig. 1c).
Seven of nine 600-mg samples (day 7) had testosterone
levels above the upper limit of quantitation for the assay.
Two samples from the 600-mg group (day 7) had
testosterone levels near the pretreatment baseline values.
One possible explanation for the absence of an increase in
serum testosterone in these two participants would be a
dosing error, but this was not reported nor verified to have
occurred. Another possible explanation is that testosterone
clearance rate was extraordinarily rapid in these two
participants. As expected, there were strong positive
correlations between changes in free and total testosterone
within and between studies, with Spearman’s correlation
ranging from 0.82 to 0.92, p<0.001.
3.3 Procollagen III/N-terminal peptide
The baseline P3NP plasma concentrations were similar in
the treatment groups within each study (Table 1). In
study 1, higher dose (300 mg) testosterone significantly
increased P3NP (1.12-fold, p=0.001), relative to placebo,
measured in healthy older men (Fig. 2a). In study 2, higher
dose (600 mg) testosterone significantly increased P3NP
(1.22-fold, p=0.007), relative to placebo, measured in
younger healthy men (Fig. 2b). There were moderate
correlations between increases in P3NP and total testosterone
within and between studies, with Spearman’sc o r r e l a t i o n
ranging from 0.41 (p=0.030) to 0.60 (p<0.001; Fig. 2c).
Significant effects of change in total testosterone (p=0.012)
and change in free testosterone (p=0.013) on change in
P3NP were observed even after adjusting for “study” and
“dose” in the regression models. Change in testosterone
explained a large proportion of treatment effect (PTE) on
Fig. 1 Testosterone administra-
tion significantly increased
both serum total and free
testosterone levels in
both young and older men
after 1-week treatment. Serum
total (a) and free testosterone
(b) increased significantly with
300 and 100 mg testosterone
IM compared with placebo
in study 1 involving healthy
60- to 75-year-old men. Serum
total (c) and free testosterone
(d) increased significantly with
600 and 200 mg testosterone
IM compared with placebo in
study 2 involving healthy 18- to
40-year-old men. Y-axis is in
log scale. Values of p, sample
size (n), mean and 90%
confidence intervals are shown
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total and free testosterone due to variability in the estimates.
3.4 Muscle protein FSR
The fractional synthesis rate for mixed muscle proteins
was calculated using the established equation: FSR=
[(increment in
13C6-phe enrichment in mixed muscle
proteins from 3 to 12 h×100)/(
13C6-phe enrichment in the
precursor pool × amount of time (h) between the two muscle
samples)] [16, 22–25]. This approach employs a reliable
estimate for
13C6-phe enrichment in the true precursor
pool for muscle protein synthesis (
13C6-aminoacyl-tRNA)
[26, 27]. The average muscle tissue free pool
13C6-phe
enrichment was used to calculate FSR. The muscle tissue
free pool
13C6-phe enrichment was 61±9% of the plasma
13C6-phe enrichment, so if plasma
13C6-phe enrichment
were used to reflect the precursor pool enrichment, the
calculated mixed muscle protein FSR would be 39% lower
(Table 2).
BaselinemixedmuscleproteinFSRwaslowinthese60-to
75-year-old men (0.048±0.009% per hour, range 0.036–
0.073% per hour). A 100-mg testosterone injection increased
muscle FSR above baseline on day 7 (p=0.041). However,
relative to placebo, average muscle FSR tended to increase
8% after 100 mg testosterone (p=0.206) and 25% after
300 mg testosterone (p=0.271; Fig. 2d). These statistical
comparisons are limited by the variable response to
testosterone (CV%=11–44%) and the small number of
participants in each group.
3.5 Muscle comparative proteomics
A primary objective for study 2 was the discovery of
protein biomarkers for muscle anabolism using proteomics
to detect peptides with statistically significant changes in
expression levels from baseline to day 7 among the
different testosterone/saline doses. A total of 83,420
features, each identified by a unique m/z and retention
time, were detected and quantified using FTMS analysis. A
subset of 65,152 features with liquid chromatography
retention times between 10 and 45 min were selected, and
platform variance was estimated to be 55% based on the
mean coefficient of variance for these features. Visual
inspection of the mass spectra for all of the samples
identified one participant’s sample with a distinctly different
Fig. 2 Plasma P3NP changes
from baseline after 1-week
testosterone treatment.
a Plasma P3NP concentration
is significantly increased
from baseline with 300 mg
testosterone (T) relative to
placebo (study 1). b Plasma
P3NP concentration is
significantly increased from
baseline with 600 mg T relative
to placebo (study 2). c Scatter
plot of change in P3NP from
baseline vs. change in total
testosterone from baseline
(study 1, filled circle; study 2,
empty triangle). A line fitted
to the points is shown (r=0.518,
p<0.001). d Change in skeletal
muscle FSR after 1-week
treatment with 300 mg
testosterone, 100 mg
testosterone, and placebo.
There were no statistically
significant changes in FSR
relative to placebo. Y-axis is
in log scale. X-axis in log scale
(c). Values of p, sample size (n),
mean, and 90% confidence
intervals are shown
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result in mass spectra that were comparable to other samples,
so this sample was excluded from further analyses. Analysis
of the 65,152 peptide features selected 692 peptide features
with statistically significant difference (p<0.01) between
baseline and day 7 for the 600-mg testosterone treatment
group. Scatter plots were created for 200 features with
the smallest mixed model p values. Figure 3a is the scatter
plot for a feature characterized by reduced expression in
the 600-mg testosterone group compared with the 200-mg
testosterone and saline groups (p<6×10
−4, −1.4-fold
change). It corresponds to a peptide matching a region of
the PDZ and LIM domain protein 3. Figure 3b depicts
another feature characterized by reduced expression in the
600-mg testosterone group compared to the 200-mg
testosterone ands a l i n eg r o u p s( p<0.0016, −1.7-fold
change). This peptide corresponds to skeletal myosin
heavy chain–light meromyosin.
3.6 Muscle mRNA differential expression
mRNA microarray analysis was used to discover gene
expression changes that might represent candidate
biomarkers associated with testosterone treatment. An
unbiased analysis of the three sets of gene expression
data (two from study 1 and one from study 2) yielded
an overlap of 12 mRNA gene expression sets we call
the muscle testosterone response (MTR) gene signature
(Table 3). These 12 mRNA expression probes correspond
to nine different genes with altered expression levels after
testosterone in comparison to baseline. There were four
genes with decreased expression (CAMTA1, CMBL,
Table 2
13C6-phe enrichment values in various precursor pools and mixed muscle protein used to calculate muscle protein synthesis rate (FSR)
Parameter Placebo (n=8) 100 mg Testosterone (n=6) 300 mg Testosterone (n=8)
Baseline Day 7 Baseline Day 7 Baseline Day 7
Plasma
13C6-phe
a 7.1±0.9 7.2±0.7 7.0±0.8 7.3±0.8 7.0±0.6 7.2±0.7
Muscle Free pool
13C6-phe
b 4.3±0.5 4.5±0.8 4.0±0.4 4.4±0.6 4.4±0.2 4.5±0.7
Mixed muscle protein
13C6-phe
c 0.0195±0.0050 0.0198±0.0017 0.0184±0.0035 0.0250±0.0091 0.0173±0.0023 0.0233±0.0081
Mixed muscle protein
synthesis rate (% per hour)
0.050±0.011 0.052±0.006 0.052±0.010 0.063±0.179 0.044±0.006 0.060±0.026
Mean ± SD. Mixed muscle protein synthesis rate calculated using muscle free pool
13C6-phe enrichment to reflect precursor pool enrichment
aAverage plasma TTR measured during 11–12 h of the tracer infusion
bAverage of 3- and 12-h muscle free pool TTR measurements
cMixed muscle protein TTR increment from 3–12 h of the tracer infusion
Fig. 3 Skeletal muscle protein expression changes after 600-mg
testosterone treatment. A plot of estimates of difference of relative
intensity for the placebo, 200-mg, and 600-mg testosterone treatment
groups at baseline (day 0) and after 1-week treatment (day 7) are
shown. Two tryptic peptides of sequence LAPNIPLEMELPGVK and
VQLLHTQNTSLINTK that correspond to the PDZ and LIM domain
protein 3 and skeletal myosin heavy chain–light meromyosin region
are shown. Y-axis is the area under the curve (AUC) on a natural log
scale for the mass spectrometry feature. Values of p determined by a
linear mixed model are shown
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sion (GINS3, PSMD8, SORT1, NINJ2, and ANKDR2).
Note that expression levels for two genes, CAMTA1 and
CMBL, were decreased after testosterone treatment on
two distinct microarray probes. One microarray RNA
probe does not encode a known gene. The expression of
these genes was converted into a composite MTR score
using partial least squares discriminant analysis (Fig. 4).
There was a dose-dependent increase in the MTR index
with increasing testosterone dose. The relative MTR
index for the 3- and 12-h muscle samples also demon-
strated the reproducibility of this biomarker (Fig. 4a).
(The RNA Microarray data will be available in the Gene
Expression Omnibus (GEO) http://www.ncbi.nlm.nih.
gov/geo/).
The RNA microarray analysis is also useful for the
validation of other biomarkers associated with testosterone
treatment and muscle anabolism. The increase in plasma
P3NP after testosterone treatment was substantiated by the
RNA microarray analysis of skeletal muscle. Expression of
collagen III, alpha-1 (COL3A1) mRNA, which encodes
P3NP, was increased with testosterone 600-mg treatment
compared with testosterone 200 mg and saline (Fig. 4c).
There were no statistically significant differences in
Gene name Gene symbol Transcript
GINS complex subunit 3 GINS3 NM_022770
Calmodulin-binding transcriptional activator 1 CAMTA1 AB020640
Carboxymethylenebutenolidase homolog CMBL ENST00000296658
Nerve-induced injury protein 2 NINJ2 NM_016533
Interferon-induced protein with tetricopeptide repeats 1 IFIT1 NM_001548
none none ENST00000358677
Fasiculation and elongation protein zeta 2 FEZ2 BC018032
Proteasome 26S subunit, non-ATPase 8 PSMD8 NM_002812
Sortilin 1 SORT1 NM_002959
Ankryin repeat domain 2 ANKRD2 NM_020349
Calmodulin binding transcription activator 1 CAMTA1 NM_015215
Carboxymethylenebutenolidase homolog CMBL NM_138809
Table 3 Muscle testosterone
response gene signature
Fig. 4 The MTR index gene signature demonstrates a dose-
dependent increase with testosterone comparing change from
baseline and 1-week treatment. a In study 1, the MTR was assessed
twice at baseline and twice after 1-week treatment; muscle biopsy
performed at 3 and 12 h after beginning the stable isotope infusion
for measuring fractional synthetic rate. For comparison between
groups, p<3.9×10
−5 (3 h) and p<2.7×10
−4 (12 h). b In study 2,
MTR was assessed once at baseline and after 1-week treatment. For
comparison between groups, p<6.2×10
−4. c Collagen 3 (COL3A1)
RNA expression is increased with the testosterone 600-mg dose
compared with testosterone 200-mg dose and placebo. The box has
horizontal lines at the lower, median, and upper quartile values.
Whiskers extend from each end of the box to the adjacent values in
the data, the most extreme values within 1.5 times the interquartile
range from the ends of the box. Outliers displayed are data with
values beyond the ends of the whiskers
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testosterone doses were compared with saline placebo in
studies 1 and 2 (data not shown and Fig. 4c).
4 Discussion
The objective of these studies was to use different but
biochemically relevant analytical platforms (transcript
profiling→protein profiling→targeted protein→protein
synthesis) to identify muscle-specific candidate early
biomarkers of testosterone-induced muscle anabolism
that would be useful in the development of novel
therapies for sarcopenia and cachexia. We confirmed that
plasma P3NP concentration is a potentially useful early
biomarker for high-dose testosterone-induced muscle
anabolism. Skeletal muscle protein and RNA profiling
analyses provided novel potential candidate biomarkers
(gene signatures) for muscle anabolism, which also
confirmed the value of plasma P3NP as an early
biomarker for muscle anabolism.
During the conversion of procollagen to collagen,
there is release of the P3NP propeptide of procollagen.
Preclinical and clinical studies measuring serum or
plasma P3NP and collagen III gene expression in muscle
have demonstrated increased levels of P3NP or procolla-
gen 3 mRNA following muscle anabolic interventions,
including resistance exercise and growth hormone treat-
ment [28–33]. As skeletal muscle protein remodels, the
collagenous perimysium and endomysium surrounding
muscle fibers must also remodel. Thus, P3NP release and
appearance in the circulation should increase as muscle
protein remodels, providing rationale that plasma P3NP
could be an early biomarker for muscle anabolism. In the
current studies, plasma P3NP increased from baseline
within 1 week of testosterone exposure. These findings are
consistent with those from the Hormonal Regulators of
Muscle and Metabolism in Aging Study involving elderly
m e nw h e r eP 3 N Pi n c r e a s e do v e rb a s e l i n ew i t h i n1 6w e e k s
of testosterone and growth hormone administration [34].
T h o u g hP 3 N Pm a yb ee l e v a t e di nd i s e a s e ds t a t e ss u c ha s
acute respiratory distress syndrome [35], liver fibrosis
[36], and myocardial infarction [37], this does not
significantly limit the clinical science utility of P3NP
because an increase in P3NP from baseline level can be
utilized. Future study participants with these potentially
confounding comorbid conditions can be excluded from
randomized controlled trials. The possibility that serum
P3NP increases are only sensitive and specific to testosterone
or growth hormone exposure needs to be addressed.
The skeletal muscle origin of P3NP, as opposed to other
tissues, is supported by the muscle RNA microarray data
indicating that high-dose (but not lower doses) testosterone
exposure increases muscle expression of COL3A;t h e
transcript that encodes collagen and is the source of
P3NP. A smaller change in serum P3NP level and muscle
COL3A1 mRNA expression may occur with lower doses of
testosterone, but this study may not have been adequately
powered to detect this small change.
In comparison to placebo, mixed muscle protein FSR
was not significantly increased 7 days after a testosterone
injection. This is in contrast to prior reports that acute
increases in mixed muscle protein FSR occur with
androgen administration [38, 39]. A single dose of
testosterone (200 mg, IM) to young men resulted in
supraphysiologic levels of total testosterone (mean=
33 nmol/L) and a twofold increase in mixed muscle FSR
after 5 days [38]. Oxandrolone administration to 72±2-
year-old men (10 mg twice daily for 5 days) increased
mixed muscle FSR 66% and to 65±2-year-old women
(7.5 mg twice daily for 14 days) increased muscle protein
FSR 57% over baseline [39]. However, neither study
included an appropriate placebo control group. These
findings suggest that higher total testosterone levels
(>19.5 nmol/L) might be necessary to significantly and
acutely increase mixed muscle protein FSR in 60- to 75-
year-old men. As suggested by Ferrando et al. [40], perhaps
testosterone reduced muscle protein breakdown rate; this
was not measured in the current study. Mixed muscle
protein synthesis was measured after an overnight fast, and
this may have limited amino acid availability for muscle
protein synthesis. Also, we may have waited too long after
the testosterone injection (7 days) to detect an increase in
mixed muscle FSR. We confirmed that resting mixed
muscle protein FSR is low in 60- to 75-year-old men
[17, 22, 24, 41–44] and lower than a previous report that
used
2H5-phe to quantify FSR in older men and women
[39]. For the purpose of identifying early biomarkers of
muscle protein anabolism-promoting therapeutic interven-
tions, serum P3NP levels, muscle protein, and transcript
profiling may be easier and less cumbersome than
quantifying in vivo mixed muscle protein FSR, but in
vivo quantitation of muscle protein FSR is the gold
standard for identifying protein anabolic interventions.
However, in this study, it only tended to increase 7 days
after testosterone injection, too few participants were
enrolled, and their response varied (potential type II error).
This limits the utility and applicability of the in vivo
measurement of mixed muscle protein FSR in the clinical
drug development setting, but it is suitable and warranted
in well-controlled physiologic research studies.
A primary objective of study 2 was the discovery of
protein biomarkers of muscle anabolism. We have previously
used this protein expression profiling approach to identify
biomarkers of pancreatitis [45], muscle injury [46], and
Alzheimer’sd i s e a s e[ 19]. We found two candidate proteomic
J Cachexia Sarcopenia Muscle (2011) 2:45–56 53markers associated with high-dose testosterone treatment:
PDZ LIM domain protein and myosin heavy chain–light
meromyosin region. The lack of a change in PDZ LIM
and myosin heavy chain–light meromyosin protein
expression with lower dose testosterone (200 mg) may
be due to the presence of a threshold effect that was
reached with testosterone 600 mg, but not with
testosterone 200 mg. Another explanation could be that
the effect of testosterone 200 mg is small, and this was
not detected given the variability of the subject response
to testosterone and the variability of the proteomics
assay method utilized. In either case, the lack of
response at 200 mg is clearly an impediment for utility
in clinical drug development since the 600-mg dose is
supraphysiological.
Microarray mRNA expression profiling of skeletal
muscle identified a set of genes (MTR gene signature)
associated with acute testosterone exposure. The genes
were selected without bias for their function in muscle.
However, several identified genes are associated with
proteins that regulate muscle anabolism. GINS complex
subunit 3 is thought to regulate DNA replication [47]. The
Calmodulin binding transcriptional activators (CAMTA) are
a family of transcription factors [48], and CAMTA2 is a
regulator of cardiac hypertrophy [49]. Nerve-induced injury
protein 2 is expressed in glial cells and is increased with
nerve injury [50]. The fasciculation and elongation protein
zeta 2 is required for neural axon outgrowth [51]. Sortilin 1
stimulates myogenic differentiation and is involved in the
glucose transport pathway in C2C12 myocytes [52]. The
Ankyrin repeat domain 2 is a titin-binding protein that
regulates skeletal muscle hypertrophy [53]. These genes are
associated with musculoskeletal and neural function and
could be used to develop direct mRNA or protein
biomarker assays for assaying muscle anabolism. The
MTR gene signature will require validation in future
clinical studies as a muscle anabolism biomarker.
In summary, plasma P3NP levels increased in a dose-
dependent manner 1 week after a single injection of
testosterone. Thus, P3NP is a potentially useful early
biomarker for muscle anabolic therapy. Skeletal muscle
protein and RNA profiling are useful tools for the
successful discovery of novel candidate muscle anabolic
biomarkers. Future studies should validate these candidate
early biomarkers (P3NP and MTR) in larger clinical studies
of longer duration and determine the association between
these early candidate biomarkers and sarcopenia-relevant
clinical endpoints, such as lean body mass, strength, and
functional improvement.
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